Condition: Solid Tumors · Hepatocellular Carcinoma (HCC) · Malignant Melanoma · Sponsor: Chiome Bioscience Inc.
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5). The purpose of this FIH study is to evaluate the safety and tolerability profile of CBA-1205.
This description comes directly from the study's public registry record.
Tanaka Miseri Chiome Bioscience Inc. · +81-3-6383-3561 · ir@chiome.co.jp
General Affairs and Human Resources Department Chiome Bioscience Inc. · +81-3-6383-3561
Always discuss trial participation with your own doctor first.
| National Cancer Center Hospital East | Kashiwa, Chiba, Japan | Recruiting |
| Kanagawa Cancer Center | Yokohama, Kanagawa, Japan | Recruiting |
| Niigata University Medical and Dental Hospital | Niigata, Niigata, Japan | Recruiting |
| National Cancer Center Hospital | Chūō, Tokyo, Japan | Recruiting |
| University of Yamanashi Hospital | Chūō, Yamanashi, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06636435